WMSA
ITCI

Weiss Multi-Strategy Advisers’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Weiss Multi-Strategy Advisers’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-10,000
Closed -$75K – 754
2019
Q3 		$75K Sell
10,000
-11,000
-52% -$105K ﹤0.01% 559
2019
Q2 		$273K Buy
+21,000
New +$269K 0.01% 457

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Weiss Multi-Strategy Advisers's ITCI Position: Q1 2024 in Review

Weiss Multi-Strategy Advisers sold out of Intra-Cellular Therapies Inc. (ITCI) in Q1 2024, closing a stake of 17,910 shares — an estimated $1.28M sold.

Weiss Multi-Strategy Advisers first reported a position in ITCI in Q2 2014 and held it in 39 quarters. The position peaked at $6.13M in Q4 2015. 346 funds tracked by Wall St. Rank hold ITCI as of Q1 2024.

  • Weiss Multi-Strategy Advisers reported no remaining Intra-Cellular Therapies Inc. position as of Q1 2024 after selling out during the quarter.
  • Weiss Multi-Strategy Advisers sold 17,910 Intra-Cellular Therapies Inc. shares in Q1 2024, an estimated $1.28M.
  • Weiss Multi-Strategy Advisers first reported a position in Intra-Cellular Therapies Inc. in Q2 2014 and held it in 39 quarters.
  • Weiss Multi-Strategy Advisers's Intra-Cellular Therapies Inc. position peaked at $6.13M in Q4 2015.
  • 346 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q1 2024.

Based on Weiss Multi-Strategy Advisers's 13F filing for Q1 2024.